Dr. Michael E. Bornstein, MD
Pediatrics (Pediatrics Physician)
At a glance
- In the NPI registry since
- 2005
Licensed in Texas since 1993, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
TX license J3747 (first issued 1993; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 13 companies reported 40 payments worth $899 in total to this clinician.
| Corium, LLC | $219 |
|---|---|
| Supernus Pharmaceuticals, Inc. | $218 |
| Baxter Healthcare | $119 |
| Cumberland Pharmaceuticals, Inc. | $61.01 |
| Medtronic, Inc. | $53.37 |
| Collegium Pharmaceutical, Inc. | $51.65 |
| UCB, Inc. | $43.06 |
| BioMarin Pharmaceutical Inc. | $32.27 |
| Food and Beverage | $780 |
|---|---|
| Long term medical supply or device loan | $119 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Baxter Healthcare Jul 15, 2025 | Long term medical supply or device loan Hillrom - Spot Vision Screener · Physical Assessment, Vision · in-kind | $119 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $491,605 in research payments for these studies, mostly to the institutions running them.
- A phase 3A, observer-blind, randomized, controlled study to evaluate t
GlaxoSmithKline, LLC. - Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Sanofi Pasteur Inc. · Active, not recruiting · NCT06736041 - Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Sanofi Pasteur Inc. · Terminated · NCT06252285 - A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
ModernaTX, Inc. · Active, not recruiting · NCT05743881 - A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age
Novavax Inc - A phase ii, single-blind, randomized, controlled study to evaluate the
GlaxoSmithKline, LLC. - A phase 2, randomized, double-blind, multi-dose, dose finding study to
GlaxoSmithKline, LLC. - Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Sanofi Pasteur Inc. · Terminated · NCT06397768
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.